Literature DB >> 24282228

Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime.

Luke J Saunders1, Richard A Russell, James F Kirwan, Andrew I McNaught, David P Crabb.   

Abstract

PURPOSE: To evaluate the proportion of patients in glaucoma clinics progressing at rates that would result in visual disability within their expected lifetime.
METHODS: This retrospective study used visual field (VF) series of at least 3 years' duration from 3790 UK patients in glaucoma clinics calculating rates of loss for each eye using linear regression of mean deviation (MD) over time. Residual life expectancies derived from the UK Office of National Statistics actuarial tables for each patient were combined with these rates to estimate predicted MDs at end of expected lifetime. The proportion of patients projected to progress to visual impairment (MD: -14 dB or worse) or statutory blindness (MD: -22 dB or worse) in both eyes before end of expected lifetime was calculated.
RESULTS: Only 3.0% (95% confidence interval [CI] 2.7%-3.4%) of patient eyes progressed at faster than -1.5 dB/year (n = 7149 eyes). Of those patients with both eyes followed, 5.2% (CI 4.5%-6.0%) were predicted to progress to statutory blindness, with a further 10.4% (CI 9.4%-11.4%) reaching visual impairment in their lifetime. More than 90% (CI 85.7%-94.3%) of patients predicted to progress to statutory blindness, had an MD worse than -6 dB in at least one eye at presentation.
CONCLUSIONS: This modeling exercise indicates that most patients in glaucoma clinics are not at high risk of progressing to statutory blindness. The likelihood of patients suffering impairment in their lifetimes is linked to VF loss at presentation, which illuminates the importance of reliably detecting significant VF defects in primary care.

Entities:  

Keywords:  glaucoma; life expectancy; perimetry; visual fields; visual function

Mesh:

Year:  2014        PMID: 24282228     DOI: 10.1167/iovs.13-13006

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  31 in total

1.  Prior rates of visual field loss and lifetime risk of blindness in glaucomatous patients undergoing trabeculectomy.

Authors:  W S Foulsham; L Fu; A J Tatham
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

2.  Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data.

Authors:  T Boodhna; L J Saunders; D P Crabb
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

3.  What rates of glaucoma progression are clinically significant?

Authors:  Luke J Saunders; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill
Journal:  Expert Rev Ophthalmol       Date:  2016-05-13

4.  Why Do People (Still) Go Blind from Glaucoma?

Authors:  Remo Susanna; Carlos Gustavo De Moraes; George A Cioffi; Robert Ritch
Journal:  Transl Vis Sci Technol       Date:  2015-03-09       Impact factor: 3.283

5.  Reducing variability in visual field assessment for glaucoma through filtering that combines structural and functional information.

Authors:  Lisha Deng; Shaban Demirel; Stuart K Gardiner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-26       Impact factor: 4.799

Review 6.  Functional assessment of glaucoma: Uncovering progression.

Authors:  Rongrong Hu; Lyne Racette; Kelly S Chen; Chris A Johnson
Journal:  Surv Ophthalmol       Date:  2020-04-26       Impact factor: 6.048

Review 7.  Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.

Authors:  C Gustavo De Moraes; Jeffrey M Liebmann; Leonard A Levin
Journal:  Prog Retin Eye Res       Date:  2016-10-20       Impact factor: 21.198

8.  Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population.

Authors:  Carmen Gruzei; Jufen Zhang; Rupert Bourne
Journal:  Int Ophthalmol       Date:  2022-01-06       Impact factor: 2.031

9.  A view on glaucoma--are we seeing it clearly?

Authors:  D P Crabb
Journal:  Eye (Lond)       Date:  2015-11-27       Impact factor: 3.775

10.  Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence.

Authors:  Mengyu Wang; Jorryt Tichelaar; Louis R Pasquale; Lucy Q Shen; Michael V Boland; Sarah R Wellik; Carlos Gustavo De Moraes; Jonathan S Myers; Pradeep Ramulu; MiYoung Kwon; Osamah J Saeedi; Hui Wang; Neda Baniasadi; Dian Li; Peter J Bex; Tobias Elze
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.